Amsel Medical Receives $7.45M Contract for Innovative Trauma Device
Amsel Medical Achieves Major Milestone with $7.45M Contract
Amsel Medical Corporation has recently announced a significant achievement in its mission to enhance trauma care. The company has been awarded a $7.45 million Phase III Small Business Innovative Research (SBIR) contract aimed at developing its innovative Temporary Vascular Occlusion Clamp (TVOC). This contract, funded by the United States Air Force, marks a pivotal moment for Amsel Medical as it endeavors to commercialize cutting-edge technology designed to control hemorrhages in emergency situations.
Revolutionizing Hemorrhage Control for Military and Civilian Settings
The awarded contract is a testament to Amsel Medical's progress, building upon previous successes with the Air Force through Phase I and II SBIR contracts. The aim of this Phase III contract is to accelerate the commercial availability of Amsel's groundbreaking haemorrhage control solution, known as SCureTO™. This device promises to revolutionize combat casualty care by providing crucial capabilities to military personnel and responders in urgent situations.
SCureTO™: A Breakthrough Device
SCureTO™ is designed to be deployed rapidly and minimally invasively in emergency settings. By allowing for arterial clamping upstream of injuries via a needle, the device seeks to address acute bleeding in a less intrusive manner. This is especially important in cases of non-compressible junctional injuries, providing a significant advantage in the field. The SCureTO™ device allows emergency responders to fine-tune the vessel occlusion and the flow of blood beyond the injury, which helps mitigate the risks associated with long-term limb ischemia and reduces the likelihood of reperfusion injury. Most critically, it extends the 'golden hour' for patients, enhancing their chances of survival and successful evacuation.
The Importance of Addressing Hemorrhage
Hemorrhage is known to be the leading cause of preventable death in military environments, accounting for up to 90% of such deaths. In civilian trauma cases, it ranks as the second leading cause. This makes the need for effective hemorrhage control solutions all the more pressing. Amsel Medical's commitment to reducing fatalities in both military and civilian contexts is reflective of its overarching mission: "Saving Limbs and Saving Lives." The SCureTO™ device stands to fulfill this mission by providing a critical resource that is both efficient and effective.
Insights from Leadership
James A. Heinz, CEO of Amsel Medical, shared his perspective on the importance of this advancement. He emphasized that trauma fatalities often occur before victims reach the hospital, highlighting the urgency for devices like SCureTO™ that can be deployed in the field. With military and civilian environments facing unique challenges, this device aims to bridge the gap in hemorrhage control capabilities, thereby saving both limbs and lives.
Expert Opinions on Future Operations
Colonel (ret) John Dorsch, a former surgeon general of the U.S. Air Force’s 24th Special Operations Wing, also commented on the potential of the SCureTO™ device. He underscored its innovative approach to controlling junctional hemorrhaging, which is often difficult to manage with traditional external tourniquets. According to him, its ability to act swiftly and effectively in non-surgical scenarios will be invaluable in future military operations, where every second counts.
Amsel Medical: Company Overview
Amsel Medical Corporation, based in Cambridge, Massachusetts, specializes in developing medical devices that focus on precision clamping technologies. Their aim is to provide reliable solutions for vessel occlusion through their innovative products, including SCureTO™ and the permanent implant SCureClamp™. The company is dedicated to advancing trauma care technology, thereby enhancing the safety and efficacy of medical responses in both military and civilian environments.
Frequently Asked Questions
What is the SCureTO™ device?
The SCureTO™ is a precision hemorrhage control solution designed for rapid and minimally invasive arterial clamping, aimed at controlling bleeding in trauma patients.
Who awarded Amsel Medical the contract?
The United States Air Force awarded Amsel Medical the $7.45 million Phase III SBIR contract.
What is the main goal of Amsel Medical?
Amsel Medical's core mission is to enhance trauma care by developing innovative medical devices that save limbs and lives.
How does SCureTO™ benefit trauma patients?
The device allows for effective hemorrhage control, extending the critical 'golden hour' for evacuation and treatment, which can significantly improve survival rates.
What are the future prospects for Amsel Medical?
With the recent contract, Amsel Medical is poised to accelerate the commercialization of its advanced trauma care solutions, potentially transforming medical responses in various situations.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Xona Accelerates Cybersecurity Investments for Government Growth
- Innovative Bioelectronic Implant Set to Transform Diabetes Treatment
- A2Z Cust2Mate Solutions Unveils Innovative Share Offering
- Benchmark Upholds Buy Rating for J.B. Hunt Amid Challenges
- EMCORE Receives Buy Upgrade Amidst Acquisition Proposals
- Republic Services Unveils Circularity Index for Sustainable Business Practices
- 5E Advanced Materials Welcomes Mark Zamek as VP for Products
- GetInsured Partners with BeWell to Transform Health Coverage
- Truist Boosts Price Target for Willis Towers Watson Amid Changes
- Mizuho's Optimistic Outlook for CVS Health's Future Prospects
Recent Articles
- Cloudflare Shares: Neutral Rating Amid Strong Revenue Gains
- Legal-Bay Expands Its Services in Hawaii for Lawsuit Funding
- BWXT's Generous Donation Boosts Tennessee Community Recovery
- Exploring the Surge of 5G RedCap Connections Toward 2030
- Goldman Sachs Keeps Sell Rating on McCormick Amid Strong Q3 Results
- Exploring the Future of the Bioadhesives Market by 2029
- BofA Adjusts Outlook on Charles Schwab Amid Interest Rate Concerns
- Blue Owl Capital Corporation Sets Earnings Call for Q3 Review
- Expert Insights on Magnite's Future: Strong Ratings & Growth
- Ameriprise Financial's Strong Performance: Insights from BofA
- TD Cowen Adjusts Paychex Target Amid Economic Challenges
- Materion Corp's Stock Outlook: Adjustments and Leadership Change
- Insights on Euro Area Yield Trends Amid Geopolitical Concerns
- Tech Giants Thrive Amid Fed Rate Cuts and AI Advances
- Understanding China's Recent Stimulus Efforts and Impacts
- StandardAero Expands IPO by 60 Million Shares at $24 Each
- Mercado Libre Faces Setbacks as JP Morgan Revises Stock Outlook
- Nike Faces Challenges Amid CEO Transition and Market Pressures
- Conflict Escalation Fuels Surge in Oil Prices Worldwide
- Explore the Future of Income with Dividend Giants Today
- Analyzing Market Trends Amid Rising Geopolitical Tensions
- Exploring the Black Pepper Market: Growth Projections and Trends
- Global Combine Harvester Market Set for Significant Growth
- Onshore Wind Energy Market Growth Projection to $180.4 Billion
- Genenta Gains Approval for Pioneering mRCC Clinical Trial
- Radisson Mining Upsizes Private Placement to $7 Million
- Vera Therapeutics Expands Atacicept Trials for Autoimmune Diseases
- Nova Minerals Partners with Whittle Consulting for Project Growth
- Vera Therapeutics Unveils Groundbreaking Atacicept Findings
- Ocugen's Innovations Highlighted at Premier Gene Meeting
- Updates on WisdomTree Natural Gas 3X Daily Securities
- Vera Therapeutics Showcases Atacicept at ASN Kidney Week 2024
- Hafnia Limited Announces Significant Changes to ISIN and CUSIP
- Genenta Launches Pioneering Trial for Renal Cell Cancer Treatment
- KalVista Pharmaceuticals Grants Equity Incentives to New Employees
- Amsel Medical Secures $7.45 Million SBIR Contract for Innovation
- Ocugen to Showcase Innovations at Upcoming Gene Meeting
- IsoEnergy's Strategic Acquisition of Anfield: Expanding Uranium Assets
- Emerging Trends in Cybersecurity Careers: A Deep Dive
- IsoEnergy Strengthens Market Position with Anfield Acquisition
- New Gold Unveils Upcoming Third Quarter Results Conference Call
- Business Architecture Guild Unveils Enhanced Vendor Program
- Rising Consumer Inflation in Ghana: A Closer Look at Trends
- Trimble Highlights Exceptional BIM Projects in Global Awards
- Ensign Group Strengthens Healthcare Facilities in Midwest
- Upcoming AT&T Analyst & Investor Day Set to Deliver Insights
- Comstock Inc. Expands into Sustainable Aviation Fuel Market
- UVA Cancer Center Joins Caris Precision Oncology Alliance
- Citi's Neutral Rating on Kimco: Price Target Steady at $24
- GameChange Solar Reaches Major Milestone with 10 GW of Projects